License to Kill Tumors: How Much Hope is Justified for Trail?

Author(s): S. Frank, A.D. Ebert

Journal Name: Current Pharmaceutical Design

Volume 7 , Issue 16 , 2001

Become EABM
Become Reviewer
Call for Editor


In 1995, a new cytokine termed TRAIL (tumor necrosis factor - related apoptosis-inducing ligand) was discovered and demonstrated to selectively induce programmed cell death in transformed cell lines. Preclinical cytotoxicity studies in mice and nonhuman primates have produced promising results by demonstrating that TRAIL exerts potent tumoricidal activity but lacks severe toxicity towards normal tissues making it a potentially ideal candidate for cancer therapy. This article reviews aspects of our current understanding of TRAIL signaling pathways and summarizes how this knowledge is currently being translated into TRAIL-based tumor-selective therapeutic strategies.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2001
Page: [1689 - 1701]
Pages: 13
DOI: 10.2174/1381612013397212
Price: $65

Article Metrics

PDF: 3